Announcements Call for Application for HEaL Institute’s Short-Duration Intensive Training Program of in Public Health Ethics to be held at Tata Institute of Social Sciences during April 14-17, 2020   |   Call for applications by The Migration Health South Asia Network for skill & capacity development training workshop to be held in 6-9 April 2020   |   Open Letter: Stop the war on Syria’s hospitals

Manufacturing the truth: From designing clinical trials to publishing trial data

Margaret Whitstock

DOI: 10.20529/IJME.2017.096


This paper expands on some of the points made by Deepak Natarajan on techniques used in designing clinical trials of new drugs to ensure favourable outcomes. It also considers the nexus between the manufacturers of new drugs and the publishers of medical journals in which edited versions of these favourable outcomes are presented to the medical fraternity. The argument will be illustrated by referring to the clinical trials of rofecoxib (Vioxx®) and etoricoxib (Arcoxia®). Both these drugs are COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) manufactured by Merck & Co. Because of the unparalleled access to Merck’s internal confidential documents, due to the subpoenaing of these documents by government and private individuals in civil and criminal actions, we are still learning about the company’s unconscionable acts. What we learn can inform our judgement concerning published reports of both new and old drugs.

Full Text





There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US